<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698109</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMIS-DIMO</org_study_id>
    <nct_id>NCT04698109</nct_id>
  </id_info>
  <brief_title>Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gynecological Diseases</brief_title>
  <acronym>BIOMIS-DIMO</acronym>
  <official_title>Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituti Tumori Giovanni Paolo II</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bari Aldo Moro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Salento</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, clinical, monocentric study aimed to collect biological samples and&#xD;
      study microbiota from subjects suffering from subjects with recurrent cervicovaginitis,&#xD;
      subjects with endometriosis, subjects with repeated implantation failures and from healthy&#xD;
      volunteers. Microbiota is a complex consortium of microorganisms, located at the mucosal&#xD;
      level (in particular intestinal, oral and vaginal) having a key role in human health and in&#xD;
      the onset of several diseases. Microbiota alterations have been found in several diseases&#xD;
      (gastrointestinal, metabolic, renal, oncological, gynaecological).&#xD;
&#xD;
      The study will allow to:&#xD;
&#xD;
        -  Provide biological samples (faeces, saliva, vaginal, urine) from healthy volunteers and&#xD;
           patients suffering from selected disease to the first Italian microbiota biobank;&#xD;
&#xD;
        -  Study microorganisms using different in vitro and in vivo techniques;&#xD;
&#xD;
        -  Study the link between the microbiota and the disease. This study is part of the BIOMIS&#xD;
           project (Project Code: ARS01_01220), presented as part of the &quot;Avviso per la&#xD;
           presentazione di progetti di ricerca industriale e sviluppo sperimentale nelle 12 aree&#xD;
           di specializzazione individuate dal PNR 2015-2020&quot; and admitted to funding under the&#xD;
           National Operational Program &quot;Ricerca e Innovazione&quot; 2014-2020 by directorial decree of&#xD;
           MIUR - Department for Higher Education and Research - n. 2298 of 12 September 2018.&#xD;
           BIOMIS includes several clinical studies that enrol patients with different pathologies&#xD;
           to collect and store biological samples and study microbiota.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this monocentric study is to populate the first national microbioma&#xD;
      biobank with biological samples (fecal, salivary, urinary and vaginsl samples) subjects&#xD;
      suffering from selected disease disease and healthy volunteers.&#xD;
&#xD;
      The secondary aim is the characterization of microorganisms of the biobank and study of the&#xD;
      microbiota-pathology relationship using meta-omics, in vitro and in vivo approaches, The&#xD;
      study plans to enrol 100 subjects at Policlinic of Bari, according to the inclusion/exclusion&#xD;
      criteria. The study participation is voluntary, and the subjects have the right to withdraw&#xD;
      from the study at any time and for any reason.&#xD;
&#xD;
      During the study, 3 visits are planned:&#xD;
&#xD;
        -  Visit 0 (V0), including description of the objectives and procedures study, signature&#xD;
           written informed consent, inclusion/exclusion criteria evaluation, medical examination&#xD;
           (blood pressure measurement, abdominal and thoracic physical examination), filling in of&#xD;
           the anamnestic questionnaire, delivery of kits for the collection of fecal, salivary and&#xD;
           urinary material to be reported at Visit 1 and delivery of a 3-day food diary, to be&#xD;
           completed autonomously in the days preceding the Visit 1.&#xD;
&#xD;
        -  Visit 1 (V1) - at least 4 days after V0, including delivery of the of the collected&#xD;
           biological material (feces, saliva, urine), and of a 3-day food diary, filling in of the&#xD;
           new signs and symptoms anamnestic questionnaire and collection of the vaginal swab by&#xD;
           medical staff.&#xD;
&#xD;
        -  Telephone evaluation: administration of a &quot;Food Frequency Questionnaire&quot; to assess the&#xD;
           subjects' alimentary habits.&#xD;
&#xD;
      Standard Operative Procedures (SOP) for samples storing, transport and processing will be&#xD;
      adopted to ensure samples stability and grant results validity and quality.&#xD;
&#xD;
      Following collections, samples will be processed in different aliquots that will be used for:&#xD;
&#xD;
        -  routine screening;&#xD;
&#xD;
        -  storage in the first Italian human microbiote biobank (I.R.C.C.S. - Istituto Tumori&#xD;
           &quot;Giovanni Paolo II&quot;, Bari);&#xD;
&#xD;
        -  evaluation of the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic&#xD;
           profile.&#xD;
&#xD;
      Furthermore, molecular characterization of pathogenic microorganisms and pathogenic biotypes&#xD;
      (pathovars) of commensal species of subjects with selected pathologies will be conducted.&#xD;
&#xD;
      Part of the biological material will be used for animal studies on the physiopathological&#xD;
      role of the human intestinal microbiota transplanted into mouse models of pathology and&#xD;
      Germ-free mouse models (specific animal study protocol developed).&#xD;
&#xD;
      The study foresees no more than minimal risk associated with blood sampling procedures. All&#xD;
      the necessary measures to avoid any risks / inconveniences resulting from participation of&#xD;
      the subject under study will be taken.&#xD;
&#xD;
      The study is compliant with Good Clinical Practice. Study protocol and all related documents&#xD;
      have been approved by approved by the Independent Ethics Committees (IEC) of the involved&#xD;
      clinical sites.&#xD;
&#xD;
      To ensure the protection and confidentiality of the participants' data, all study activities&#xD;
      will be carried out in accordance with the European General Data Protection Regulation,&#xD;
      Regulation (EU) 2016/679, which repeals Directive 95/46/EC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biological samples collection for establishment of the first National Microbiome Biobank</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Recruitment of 100 subjects (patients with recurrent cervicovaginitis, endometriosis, repeated implantation failures and healthy volunteers) to collect biological samples for establishment of the first National Microbiome Biobank</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cervicovaginitis</condition>
  <condition>Endometriosis</condition>
  <condition>Repeated Implantation Failure</condition>
  <arm_group>
    <arm_group_label>recurrent cervicovaginitis</arm_group_label>
    <description>patients with recurrent cervicovaginitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endometriosis</arm_group_label>
    <description>patients with endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>repeated implantation failures</arm_group_label>
    <description>patients with repeated implantation failures</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <description>healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological sample collection</intervention_name>
    <description>Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening</description>
    <arm_group_label>endometriosis</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>recurrent cervicovaginitis</arm_group_label>
    <arm_group_label>repeated implantation failures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire</description>
    <arm_group_label>endometriosis</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>recurrent cervicovaginitis</arm_group_label>
    <arm_group_label>repeated implantation failures</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical examination</intervention_name>
    <description>Blood pressure measurement, abdominal and thoracic physical examination</description>
    <arm_group_label>endometriosis</arm_group_label>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>recurrent cervicovaginitis</arm_group_label>
    <arm_group_label>repeated implantation failures</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      faeces, saliva, vaginal swab, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of recurrent cervicovaginitis, of endometriosis and subjects with&#xD;
        repeated implantation failures attending to the clinical centres involved in the study.&#xD;
&#xD;
        Healthy volunteers will be recruited by invitation. Enrolled subjects must not have any&#xD;
        family relationship and hierarchical subordination with the hospitals in which biological&#xD;
        samples will be collected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HEALTHY VOLUNTEERS&#xD;
&#xD;
          -  healthy subjects aged between 18 and 45 years, in reproductive age&#xD;
&#xD;
          -  BMI between 18.5-30&#xD;
&#xD;
          -  omnivorous diet&#xD;
&#xD;
          -  signature of the informed consent&#xD;
&#xD;
        PATIENTS WITH RECIDIVING CERVIC VAGINITIS&#xD;
&#xD;
          -  healthy subjects aged between 18 and 45 years, in reproductive age&#xD;
&#xD;
          -  Patients suffering from at least 3 episodes of relapsing cervicovaginitis per year:&#xD;
             diagnosis of anaerobic vaginitis (AV) or bacterial vaginosis (BV) or vulvo-vaginal&#xD;
             candidiasis (VVC) based on clinical symptoms and positive microscopic examination and&#xD;
             / or positive vaginal culture&#xD;
&#xD;
          -  BMI between 18.5-30&#xD;
&#xD;
          -  omnivorous diet&#xD;
&#xD;
          -  signature of the informed consent&#xD;
&#xD;
        PATIENTS WITH ENDOMETRIOSIS&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  aged between 18 and 45 years, in reproductive age&#xD;
&#xD;
          -  patients with endometriosis: diagnosis of endometriosis carried out with transvaginal&#xD;
             ultrasound with associated elevation of CA125&#xD;
&#xD;
          -  BMI between 18.5-30&#xD;
&#xD;
          -  omnivorous diet&#xD;
&#xD;
          -  signature of the informed consent&#xD;
&#xD;
        PATIENTS WITH REPEATED IMPLANT FAILURES (RIF)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  age between 18 and 45 years in reproductive age&#xD;
&#xD;
          -  patients with RIF: patients who have followed PMA protocols with at least 3 failed&#xD;
             attempts after transfer of good quality embryos&#xD;
&#xD;
          -  BMI between 18.5-30&#xD;
&#xD;
          -  omnivorous diet&#xD;
&#xD;
          -  signature of the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        HEALTHY VOLUNTEERS&#xD;
&#xD;
          -  Current or previous infectious diseases (HAV, HBV, HCV, HIV, Cytomegalovirus,&#xD;
             Epstein-Barr virus)&#xD;
&#xD;
          -  HPV positive&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  History of Clostridium difficile infections&#xD;
&#xD;
          -  Recent (&lt;3 months) therapy with antibiotics, immunosuppressive drugs, chemotherapy&#xD;
&#xD;
          -  Chronic therapy with proton pump inhibitors&#xD;
&#xD;
          -  Recent (&lt;3 months) use of probiotics, laxatives or other aids (drugs / supplements)&#xD;
             for the regulation of gastrointestinal activity&#xD;
&#xD;
          -  Previous history of organ / tissue transplantation&#xD;
&#xD;
          -  Recent onset of diarrhea&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Chronic constipation&#xD;
&#xD;
          -  Previous gastrointestinal surgery (eg gastric bypass)&#xD;
&#xD;
          -  Recurring urinary tract infections (3 cases per year)&#xD;
&#xD;
          -  Previous major acute cardiovascular diseases (myocardial infarction, stroke)&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  eGFR (estimated glomerular filtration rate) lower than 60ml / minute and / or&#xD;
             diagnosis of nephropathy&#xD;
&#xD;
          -  Chronic gastrointestinal disorders&#xD;
&#xD;
          -  Systemic inflammatory diseases&#xD;
&#xD;
          -  Suspicion, clinical diagnosis or previous history of cancer (&lt;5 years)&#xD;
&#xD;
          -  Autoimmune disorders or history of chronic and systemic autoimmune disorders&#xD;
&#xD;
          -  Neurodegenerative disorders&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Hormonal and / or intrauterine contraceptive therapy&#xD;
&#xD;
          -  Healthcare workers&#xD;
&#xD;
          -  Operators work with animals&#xD;
&#xD;
          -  Psychiatric conditions that reduce protocol compliance.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        POPULATION 2 - PATIENTS WITH RECIDIVING CERVIC VAGINITIS/ POPULATION 3 - PATIENTS WITH&#xD;
        ENDOMETRIOSIS/ POPULATION 4 - PATIENTS WITH REPEATED IMPLANT FAILURES (RIF)&#xD;
&#xD;
          -  Current or previous infectious diseases (HAV, HBV, HCV, HIV, Cytomegalovirus,&#xD;
             Epstein-Barr virus)&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  History of Clostridium difficile infections&#xD;
&#xD;
          -  Recent (&lt;3 months) therapy with antibiotics, immunosuppressive drugs, chemotherapy&#xD;
&#xD;
          -  Chronic therapy with proton pump inhibitors&#xD;
&#xD;
          -  Recent (&lt;3 months) use of probiotics, laxatives or other aids (drugs / supplements)&#xD;
             for the regulation of gastrointestinal activity&#xD;
&#xD;
          -  Previous history of organ / tissue transplantation&#xD;
&#xD;
          -  Recent onset of diarrhea&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Chronic constipation&#xD;
&#xD;
          -  Previous gastrointestinal surgery (eg gastric bypass)&#xD;
&#xD;
          -  Recurring urinary tract infections (3 cases per year)&#xD;
&#xD;
          -  Previous major acute cardiovascular diseases (myocardial infarction, stroke)&#xD;
&#xD;
          -  Type 2 diabetes mellitus&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  eGFR (estimated glomerular filtration rate) lower than 60ml / minute and / or&#xD;
             diagnosis of nephropathy&#xD;
&#xD;
          -  Chronic gastrointestinal disorders&#xD;
&#xD;
          -  Systemic inflammatory diseases&#xD;
&#xD;
          -  Suspicion, clinical diagnosis or previous history of cancer (&lt;5 years)&#xD;
&#xD;
          -  Autoimmune disorders or history of chronic and systemic autoimmune disorders&#xD;
&#xD;
          -  Neurodegenerative disorders&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Hormonal and / or intrauterine contraceptive therapy&#xD;
&#xD;
          -  Healthcare workers&#xD;
&#xD;
          -  Operators work with animals&#xD;
&#xD;
          -  Psychiatric conditions that reduce protocol compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ettore Cicinelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ettore Cicinelli, MD</last_name>
    <phone>0039-080-5478985</phone>
    <email>ettore.cicinelli@uniba.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dipartimento di Scienze biomediche e oncologia umana (DIMO), Sezione di Ginecologia ed Ostetricia II Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ettore Cicinelli, MD</last_name>
      <phone>0039-080-5478985</phone>
      <email>ettore.cicinelli@uniba.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ma D, Chen Y, Chen T. Vaginal microbiota transplantation for the treatment of bacterial vaginosis: a conceptual analysis. FEMS Microbiol Lett. 2019 Feb 1;366(4). pii: fnz025. doi: 10.1093/femsle/fnz025. Review.</citation>
    <PMID>30715301</PMID>
  </reference>
  <reference>
    <citation>Yuan M, Li D, Zhang Z, Sun H, An M, Wang G. Endometriosis induces gut microbiota alterations in mice. Hum Reprod. 2018 Apr 1;33(4):607-616. doi: 10.1093/humrep/dex372.</citation>
    <PMID>29462324</PMID>
  </reference>
  <reference>
    <citation>Smith SB, Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol. 2017 Jan 15;595(2):451-463. doi: 10.1113/JP271694. Epub 2016 May 5. Review.</citation>
    <PMID>27373840</PMID>
  </reference>
  <reference>
    <citation>Laschke MW, Menger MD. The gut microbiota: a puppet master in the pathogenesis of endometriosis? Am J Obstet Gynecol. 2016 Jul;215(1):68.e1-4. doi: 10.1016/j.ajog.2016.02.036. Epub 2016 Feb 18.</citation>
    <PMID>26901277</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbioma biobank</keyword>
  <keyword>Biological human samples</keyword>
  <keyword>genital system disease</keyword>
  <keyword>Meta-omics approaches</keyword>
  <keyword>Microbiota-pathology relationship</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

